期刊文献+

高效液相色谱法测定腹腔热灌注化疗后腹腔液及血浆的顺铂浓度

High-performance liquid chromatography-based determination of human plasma and ascites cisplatin levels after hyperthermic intraperitoneal perfusion chemotherapy
原文传递
导出
摘要 目的:建立高效液相色谱法测定腹腔热灌注化疗后腹腔液及血浆顺铂浓度。方法:采用高效液相色谱法测定腹腔热灌注化疗完成后血浆和腹腔液中的顺铂浓度,即经二乙基二硫代氨基甲酸钠络合衍生化后用流动相溶解的产物Pt(DDTC)2的浓度。色谱柱为Hypersil-ODS2(250 mm×4.6 mm,5μm),流动相为水-乙腈(30∶70),流速1.0 mL·min-1,检测波长254 nm,柱温25℃。结果:顺铂的血浆检测线性范围为0.1~1.5μg·mL-1(r2=0.9997),平均回收率99.6%(n=6);顺铂的腹腔液检测线性范围为2~25μg·mL-1(r2=0.998 8),平均回收率100.7%(n=6),最低检测浓度均为0.1μg·mL-1。利用已建立的方法,本研究还对5位行腹腔热灌注化疗的患者进行了血浆及腹腔液顺铂药物浓度检测。发现腹腔热灌注化疗结束后顺铂平均吸收率98.38%。结论:本法是一种准确有效的检测方法,适用于腹腔热灌注化疗后血浆及腹腔液顺铂药物浓度监测和药动学研究,为后续设计针对化疗药物浓度监测的临床实验提供了技术基础。 Objective:To develop an HPLC methodss for determining human plasma and ascites concentrations of cisplatin(DDP)after hyperthermic intraperitoneal perfusion chemotherapy(HIPEC). Methods:DDP was extracted from the human plasma and ascites DDP and reacted with sodium diethyldithioearbamate(DDTC). The product Pt(DDTC)2 extracted by acetonitrile ether was determined using high-performance liquid chromatography(HPLC)with the mobile phase of water and acetonitrile at the ratio of 30∶70 and the flow rate of 1.0 mL·min-1.The separation was performed on a Hypersil-ODS2 column(250 mm×4.6 mm,5 μm)with column temperature at 25 ℃. The derivatives of DDP were detected at the wavelength of 254 nm. Results:The linear ranges of DDP were 0.1-1.5 μg·mL-1 for plasma(r2=0.999 7)and 2-25 μg·mL-1 for ascites(r2=0.998 8). The average recoveries of DDP were 99.6% for plasma(n=6)and 100.7% for ascites(n=6). The minimum concentration detectable was 0.1 μg·mL-1. Using the established methods,plasma and peritoneal fluid concentrations of cisplatin were detected in 5 patients undergoing HIPEC. It was found that the average absorption rate of cisplatin was 98.38% after HIPEC. Conclusion:The method is accurate and effective for determining plasma and ascites DDP levels after HIPEC and it can be used in pharmacokinetic study and concentration monitoring of DDP. It provided a technical basis for the subsequent design of clinical trials for monitoring the concentration of DDP.
作者 彭雪婷 李康 袁达伟 张鑫 王璇 王田田 张琼驰 闫融 潘士印 PENG Xue-ting;LI Kang;YUAN Da-wei;ZHANG Xin;WANG Xuan;WANG Tian-tian;ZHANG Qiong-chi;YAN Rong;PAN Shi-yin(Xi’an Jiaotong University Health Science Center,Xi’an 710061,China;Department of Surgical Oncology,The First Afflicted Hospital of Xi’an Jiaotong University,Xi’an 710061,China;Shaanxi Institute of Ophthalmology,Shaanxi Key Laboratory of Ophthalmology,Xi’an No.1 Hospital,Xi’an 710002,China)
出处 《药物分析杂志》 CAS CSCD 北大核心 2020年第3期470-476,共7页 Chinese Journal of Pharmaceutical Analysis
关键词 高效液相色谱法 腹腔热灌注 顺铂 血药浓度 腹腔液药物浓度 high-performance liquid chromatography hyperthermic intraperitoneal perfusion chemotherapy cisplatin plasma drug concentration ascites drug concentration
  • 相关文献

参考文献5

二级参考文献61

  • 1杜楠,赵辉,王海滨,李晓松,付艳,范忠义,陈殿君,孙君重,高珂.顺铂联合贝伐珠单抗对老年肺癌胸腔积液血管内皮生长因子表达的影响及疗效观察[J].中华临床医师杂志(电子版),2012,6(20):72-75. 被引量:18
  • 2孙燕,石远凯.临床肿瘤内科分册[M].北京:人民卫生出版社,2008:147-149.
  • 3McKeage MJ. Lobaplatin: a new antitumour platinum drug [ J ]. Expert Opin Investig Drugs, 2001, 10 ( 1 ) : 119 - 128.
  • 4JEMAL A, BRAY F, CENTER M M, et al. Globalcancer statistics[J].CA Cancer J Clin, 2011,61(2):69-90.
  • 5OHTSU A, YOSHIDA S, SAIJO N. Disparities ingastric cancer chemotherapy between the East andWestUlJ C"n Oncol, 2006, 24(14):2188-2196.
  • 6WAGNER A D,UNVERZACT S, GROTHE W, et al.Chemotherapy for advanced gastric cancer[J].Cochrane Database Syst Rev, 2010, 1 7(3):CD004064.
  • 7POWER D G, KELSEN D P, SHAH M A. Advancedgastric cancer一Slow but steady progress[J].Cancer Treat Rev, 2010, 36(5):384-392.
  • 8SHITARA K, MATSUO K, MIZOTA A, et al.Association of fluoropyrimidines, platinumagents, taxanes, and irinotecan in any line ofchemotherapy with survival in patients withadvanced gastric cancer[J].Gastric Cancer, 2011,14(2):155-160.
  • 9WAGNER A D, GROTHE W, HAERTING J, et al.Chemotherapy in advanced gastric cancer: asystematic review and meta-analysis basedon aggregate data[J]. J Clin Oncol, 2006,24(18):2903-2909.
  • 10AJANI J A. Evolving chemotherapy for advancedgastric cancer[J] Oncologist, 2005,1 0(Suppl3):49-58.

共引文献116

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部